RTH258 Brolucizumab Clinical Trials

Description

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.